egfrtkis通过阻断akt下调pdl1在egfr突变型 非小细胞肺癌中的表达word格式论文.docx

优秀毕业论文 精品参考文献资料 目 录 中文摘要 ·············································································1 英文摘要 ·············································································4 英文缩写 ·············································································8 研究论文 EGFR-TKIs 通过阻断 AKT 下调 PD-L1 在 EGFR 突变型非小细胞 肺癌中的表达机制 前言 ·············································································9 材料与方法 ····································································11 结果 ·············································································21 附图 ·············································································23 附表 ·············································································30 讨论 ·············································································32 结论 ·············································································33 参考文献 ·······································································34 综述 PD-1/PD-L1 信号通路及其阻滞剂在非小细胞肺癌（NSCLC）中的研 究进展 36 致谢 ···················································································46 个人简历 ·············································································47 中 文 摘 要  PAGE 7 万方数据 EGFR-TKIs 通过阻断 AKT 下调 PD-L1 在 EGFR 突变型非小细胞肺 癌中的表达 摘 要 目的：肺癌是全球范围内发病率和死亡率居首位的恶性肿瘤。对于晚 期非小细胞肺癌，近年来继传统的放化疗外，分子靶向治疗和免疫治疗成 为非小细胞肺癌治疗领域的最重要的手段之一，其个体化的精准性和高效 性使之成为大家研究关注的焦点。其中作为比例最高的驱动基因靶点表皮 生长因子受体（ Epidermal Growth Factor Receptor, EGFR ），和免疫治疗 靶点PD-1和PD-L1最为引人瞩目。分别针对性的靶向药物的抗肿瘤效果在 体外和体内试验中已得到充分的验证。既往部分研究发现，EGFR信号通 路与PD-1/PD-L1之间存在某种联系，本研究旨在进一步确定二者之间的 相关性及机制，以及EGFR-TKIs是否通过阻断EGFR通路抑制肿瘤增殖同 时对 PD-L1表达产生影响 。 方法： 1 细 胞 培 养 使 用 含 有 10% 胎 牛 血 清 的 1640 培养 基 常 规 传 代 培 养 HCC827细胞，并置于含有5%C02、95%、37℃湿度的恒温培养箱中培养。 2 MTT 法检测 一定浓度梯度厄洛替尼对人非小细胞肺癌细 胞 HCC827增殖的抑制作用，然后检测药物作用24h后HCC827细胞活性，并 且计算药物半数抑制浓度（IC50），绘制生长曲线图。 3 应用流式细胞仪检测生长因子EGF刺激HCC827前后及厄洛替尼作 用细胞后PD-L1表达的情况。 4 应用Transwell实验技术检测生长因子EGF刺激HCC827前后和厄洛 替尼作用于HCC827细胞前后，肺癌细胞的转移能力的变化情况。 5 应用流式细胞仪检测生长因子EGF刺激HCC827细胞前后以及